Larimar Therapeutics Inc (LRMR)
7.035
-0.26
(-3.50%)
USD |
NASDAQ |
Jun 25, 16:00
7.035
0.00 (0.00%)
After-Hours: 20:00
Larimar Therapeutics Cash from Operations (Quarterly): -10.41M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -10.41M |
| December 31, 2023 | -9.343M |
| September 30, 2023 | -9.20M |
| June 30, 2023 | -7.365M |
| March 31, 2023 | -7.551M |
| December 31, 2022 | -6.672M |
| September 30, 2022 | -5.878M |
| June 30, 2022 | -7.486M |
| March 31, 2022 | -7.533M |
| Date | Value |
|---|---|
| December 31, 2021 | -7.918M |
| September 30, 2021 | -12.20M |
| June 30, 2021 | -10.78M |
| March 31, 2021 | -11.21M |
| December 31, 2020 | -9.857M |
| September 30, 2020 | -11.22M |
| June 30, 2020 | -12.20M |
| March 31, 2020 | -8.921M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-12.20M
Minimum
Jun 2020
-5.878M
Maximum
Sep 2022
-9.161M
Average
-9.20M
Median
Sep 2023
Cash from Operations (Quarterly) Benchmarks
| Biogen Inc | 553.20M |
| Eli Lilly and Co | 1.166B |
| PTC Therapeutics Inc | 70.76M |
| Design Therapeutics Inc | -12.44M |
| CEL-SCI Corp | -4.528M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -68.36M |
| Cash from Financing (Quarterly) | 162.15M |
| Free Cash Flow | -36.32M |
| Free Cash Flow Per Share (Quarterly) | -0.1944 |
| Free Cash Flow Yield | -11.15% |